Legal
Trump's 100% Pharma Tariffs Carve Out Half the Industry
Trump's 100% Section 232 pharma tariffs exempt 13 drugmakers, generics, and trade-deal nations. Mid-sized biotechs are most at risk. Exemptions expire 2029.
Latest — Page 24
Deals
Neurocrine Buys Soleno for $2.9B, Betting 15x Revenue on Rare Hunger Drug
Neurocrine is paying $2.9B at ~15x trailing revenue for Soleno's Vykat XR, the only approved drug for Prader-Willi hunger, in its biggest-ever deal.
Deals
Anthropic Drops $400M on Six-Person Drug Discovery Startup
Anthropic acquires six-person AI biotech Coefficient Bio for $400M in stock — $66M per employee for a company founded in 2025 with no public product.
Deals
Takeda Walks Away From $150M Denali Dementia Bet After 8 Years
Takeda returns frontotemporal dementia drug DNL593 to Denali after 8 years and $150M, citing strategy—not safety—days after Denali's FDA approval win.
FDA
Amgen's $27.8B Drug Gets Easier — Tepezza Shot Matches IV
Amgen's phase 3 shows subcutaneous Tepezza via on-body injector hits 77% response rate, matching IV efficacy, potentially expanding the flat $1.9B drug's reach.
Deals
Anthropic Pays $400M for a 10-Person Ghost Company
Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.
Deals
Stipple Bio Raises $100M to Pinpoint Cancer Drug Targets
Stipple Bio launches with $100M to identify precise targets on cancer proteins, betting the ADC industry's real problem is aim, not ammo.
Deals
Neurocrine Pays $2.9B for Soleno's Prader-Willi Drug
Neurocrine pays $53/share in cash for Soleno Therapeutics, acquiring Vykat XR, a profitable approved treatment for Prader-Willi syndrome.
Deals
Gilead Cuts 51 Foster City Jobs One Year After Same Layoff
Gilead cuts 51 Foster City jobs effective May 29, one year after the same HQ shed 149. The backdrop: ~$10B in acquisitions closed since February.
FDA
Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%
Lipocine's oral brexanolone failed Phase 3 for postpartum depression, wiping 77% off its stock. The pill version of Zulresso didn't work.
FDA
Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data
Novo Nordisk published rival efficacy data the day after FDA approved Lilly's oral obesity pill Foundayo — but no head-to-head trial exists to back the claims.
FDA
Pfizer Scraps COVID Vaccine Trial; 80% of Recruits Failed Screening
Pfizer and BioNTech shut down their 25,000–30,000-person COVID trial after 80%+ of recruits failed screening, leaving FDA-required approval data ungenerated.
FDA
White House Asks for $15.8B HHS Cut — Congress Already Said No Once
White House requests $15.8B HHS cut for FY2027, including a $5B NIH reduction and three institute eliminations. Congress rejected a bigger ask last year.
Deals
Syneron Bio Pulls $150M Series B Four Months After $100M Round
Syneron Bio raises $150M Series B, bringing total funding to $250M in four months, backed by AstraZeneca and Abu Dhabi sovereign wealth.
Deals
OpenEvidence Buys Tandem to Automate Prior Authorization
OpenEvidence acquires Tandem to add AI-driven prior authorization to its doctor-facing platform, threatening standalone PA automation vendors.
